Skip to main content
Book a call — £89
Menu

Intellectual Property in the Pharmaceutical Industry | LegalDocuments.co.uk

We're not a law firm — we help you find the right legal support. For advice on your situation, speak to a legal adviser or find a solicitor.

Part ofIP Rights

Written by Brad Askew Solicitor (non-practising)
Brad is on the roll of solicitors of England & Wales but does not hold a practising certificate and does not provide legal advice.
Updated June 2026 · England & Wales
Few industries depend on intellectual property quite like pharmaceuticals. The cost of taking a compound from a laboratory bench through clinical trials and onto pharmacy shelves can run into hundreds of millions, and without robust legal protection that investment would be impossible to justify. IP rights give pharmaceutical companies the breathing room to recoup what they have spent on research, while also setting the terms under which generics eventually enter the market and bring prices down for patients. This guide, written from a UK perspective, walks through the main forms of protection available, how they interact with medicines regulation, and the strategic decisions that founders, in-house counsel and licensing teams tend to face. I have tried to keep it practical rather than academic, with an eye on the questions that actually come up in commercial conversations.

Overview

Intellectual property in the pharmaceutical context is the collection of legal rights that let a company control who can make, sell or use its innovations. In the UK these rights sit across several regimes. Patents, governed by the Patents Act 1977, protect new compounds, formulations, manufacturing processes and second medical uses for a limited period.

Supplementary Protection Certificates (SPCs) can extend patent-like protection to compensate for time lost to regulatory approval. Data and market exclusivity rules, administered through the Medicines and Healthcare products Regulatory Agency (MHRA), restrict when a generic competitor can rely on the originator's clinical trial data.

Trade marks protect brand names and packaging, while trade secrets cover confidential know-how such as manufacturing recipes and proprietary screening methods. Copyright and database rights can protect scientific datasets and software used in drug discovery. These rights operate together rather than in isolation, and a well-designed portfolio usually layers several of them around a single product so that expiry of one right does not leave the whole asset unprotected.

Key steps

  1. Map the invention early. Before any public disclosure, sit down with the research team and identify every patentable concept: the active compound, salt forms, formulations, dosage regimens, manufacturing steps and second medical uses. Disclosure at a conference or in a journal before filing can destroy novelty, so the audit needs to happen well ahead of any external presentation or publication.
  2. Plan the filing route. Decide whether to start with a UK application at the Intellectual Property Office, a European filing at the EPO, or an international PCT application that buys time before committing to individual countries. The right choice depends on where the commercial market sits, where manufacturing will happen, and how much budget is available during the priority year to develop the invention further.
  3. Build layered protection. A single compound patent is rarely enough. Consider follow-on filings for improved formulations, combination therapies, paediatric dosing and new indications as the clinical programme progresses. Each layer can extend the effective commercial life of the product, though care is needed to avoid evergreening challenges from regulators and generic competitors.
  4. Coordinate with regulatory strategy. Patent timelines and MHRA authorisation timelines need to be managed together. An SPC application, for example, must be filed within six months of the first UK marketing authorisation or within six months of grant of the basic patent, whichever is later. Missing that window forfeits valuable extra protection, so the regulatory and IP teams need to talk regularly.
  5. Monitor, enforce and license. Once rights are granted, watch the market for infringing products, review generic launches at patent expiry, and consider licensing arrangements that can generate revenue from territories or uses you will not exploit directly. Enforcement in the UK typically runs through the Patents Court or the Intellectual Property Enterprise Court, and the choice of forum affects cost and speed significantly.
If you're dealing with this kind of situation, a call with an experienced legal adviser can help you work out the right next step — from £149.

Common questions

Q How long does a pharmaceutical patent last in the UK?
A UK patent lasts for up to 20 years from the filing date, subject to payment of annual renewal fees. For medicines, a Supplementary Protection Certificate can add up to a further five years of protection to compensate for time taken obtaining marketing authorisation. Paediatric extensions may add another six months where the relevant conditions are met. The effective commercial life is usually much shorter than 20 years because of clinical trial timelines.
Q What is data exclusivity and how is it different from a patent?
Data exclusivity is a regulatory protection that prevents generic manufacturers from relying on the originator's clinical trial data when seeking their own marketing authorisation. In the UK the standard period is typically eight years of data exclusivity plus two years of market exclusivity. It runs independently of any patent and can protect a product even where patent coverage is weak, which is why it matters for commercial planning.
Q Can you patent a second medical use of an existing drug?
Yes, in many cases. UK and European patent law allows claims to a known substance for use in treating a new medical condition, often drafted in the so-called Swiss-style format or as purpose-limited product claims. These patents are valuable but can be harder to enforce, particularly where prescribing and dispensing decisions make it difficult to prove that a generic product is being used for the patented indication.
Q What role do trade secrets play alongside patents?
Trade secrets protect information such as manufacturing processes, formulation know-how and proprietary assay methods that either cannot be patented or are better kept confidential. Unlike patents they have no fixed term and protection lasts as long as the information stays secret. They depend on practical measures like confidentiality agreements, restricted access and staff training, and losing control of the information usually means losing the right.
Q How are pharmaceutical patent disputes usually resolved in the UK?
Most contested pharmaceutical patent cases in the UK are heard in the Patents Court, which is part of the Business and Property Courts. More straightforward or lower-value disputes can go to the Intellectual Property Enterprise Court, which caps costs and damages. Many disputes settle through licensing or pay-for-delay arrangements, though the latter attract competition law scrutiny from the Competition and Markets Authority.
Q Does Brexit affect pharmaceutical IP protection in the UK?
European patents granted by the EPO continue to cover the UK because the European Patent Convention is not an EU instrument. However, the SPC regime now operates as a UK-specific system, and marketing authorisations are granted separately by the MHRA rather than centrally through the EMA. Companies planning filings or launches need to treat the UK as a distinct jurisdiction from the EU for regulatory and some IP purposes.
Q What is evergreening and is it lawful?
Evergreening is the practice of filing successive patents on minor variations of an existing drug to extend market exclusivity. The practice itself is not unlawful, but individual patents still have to meet the tests of novelty and inventive step, and courts have struck down weak follow-on patents. Competition authorities also scrutinise behaviour that combines evergreening with conduct designed to delay generic entry beyond what the IP rights justify.
If you're dealing with this kind of situation, a call with an experienced legal adviser can help you work out the right next step — from £149.

Sources

This guide is based on primary UK law and official guidance.

Brad Askew, Solicitor (non-practising)

Written & reviewed by

Brad Askew Solicitor (non-practising)

Brad is on the roll of solicitors of England & Wales but does not hold a practising certificate and does not provide legal advice. LegalDocuments.co.uk is not a law firm and does not provide regulated legal advice.

Full profile →SRA register ↗
Legal disclaimer
This article is for general information only. It is a tool to help you find your way — not legal advice, and not a substitute for speaking to a qualified adviser about your situation.